MARK POWELL, M.D.
Osteopathic Medicine at Ogden Dr, Burlingame, CA
License number
California G35190
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
2
1820 Ogden Dr FLOOR SECOND, Burlingame, CA 94010
100 Vista Grande, San Rafael, CA 94904
100 Vista Grande, San Rafael, CA 94904
Phone
(650) 697-7202
(415) 461-3320
(415) 461-3320
Professional information
Dr. Mark Powell, Burlingame CA - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
1820 Ogden Dr STE 2ND, Burlingame 94010
(650) 697-7202 (Phone)
(650) 697-7202 (Phone)
Certifications:
Internal Medicine, 1981
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Rosalind Franklin University of Medicine and Science / Chicago Medical School
Graduated: 1976
Rosalind Franklin University of Medicine and Science / Chicago Medical School
Graduated: 1976
Modulators Of B-Lymphocyte Activation, Myosin-1F Compositions And Methods Of Use
US Patent:
6890725, May 10, 2005
Filed:
Jul 23, 2002
Appl. No.:
10/202481
Inventors:
Marcy K. Vallone - San Francisco CA, US
Brian R. Wong - San Mateo CA, US
Esteban Masuda - Menlo Park CA, US
Mark Powell - Burlingame CA, US
Brian R. Wong - San Mateo CA, US
Esteban Masuda - Menlo Park CA, US
Mark Powell - Burlingame CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C12Q001/42, G01N033/53
US Classification:
435 724, 435 721, 435 21
Abstract:
The present invention provides compositions and methods for modulating B-lymphocyte activation. Nucleic acids encoding proteins and proteins so encoded which are capable of modulating B-lymphocyte activation are provided. Compositions and methods for the treatment of disorders related to dysfunction or dysregulation of B-lymphocyte activation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating B-lymphocyte activation.
Modulators Of B-Lymphocyte Activation, Myosin-1F Compositions And Methods Of Use
US Patent:
7371537, May 13, 2008
Filed:
Apr 27, 2005
Appl. No.:
11/116725
Inventors:
Marcy K. Vallone - San Francisco CA, US
Brian R. Wong - San Mateo CA, US
Esteban Masuda - Menlo Park CA, US
Mark Powell - Burlingame CA, US
Brian R. Wong - San Mateo CA, US
Esteban Masuda - Menlo Park CA, US
Mark Powell - Burlingame CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C02K 1/00, G01N 33/53
US Classification:
435 724, 435 4, 435 6, 435 721, 435 21
Abstract:
The present invention provides compositions and methods for modulating B-lymphocyte activation. Nucleic acids encoding proteins and proteins so encoded which are capable of modulating B-lymphocyte activation are provided. Compositions and methods for the treatment of disorders related to dysfunction or dysregulation of B-lymphocyte activation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating B-lymphocyte activation.
Modulators Of Leukocyte Activation, Bic Compositions And Methods Of Use
US Patent:
6929923, Aug 16, 2005
Filed:
Jul 23, 2002
Appl. No.:
10/202480
Inventors:
Marcy K. Vallone - San Francisco CA, US
Brian R. Wong - Los Altos CA, US
Esteban Masuda - Menlo Park CA, US
Mark Powell - Burlingame CA, US
Brian R. Wong - Los Altos CA, US
Esteban Masuda - Menlo Park CA, US
Mark Powell - Burlingame CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C12Q001/02
US Classification:
435 724, 435 29
Abstract:
The present invention provides compositions and methods for modulating leukocyte activation. Nucleic acids encoding proteins and proteins so encoded which are capable of modulating leukocyte activation are provided. Compositions and methods for the treatment of disorders related to leukocyte dysfunction or dysregulation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating leukocyte activation.
Modulators Of Leukocyte Activation, Hck Compositions And Methods Of Use
US Patent:
7067266, Jun 27, 2006
Filed:
Jul 10, 2002
Appl. No.:
10/193720
Inventors:
Annabelle Friera - South San Francisco CA, US
Brian R. Wong - San Mateo CA, US
Esteban Masuda - Menlo Park CA, US
Mark Powell - Burlingame CA, US
Brian R. Wong - San Mateo CA, US
Esteban Masuda - Menlo Park CA, US
Mark Powell - Burlingame CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C12Q 1/02, C12Q 1/48, G01N 33/566
US Classification:
435 724, 435 15, 435 29, 436 63, 436501
Abstract:
The present invention provides compositions and methods for modulating leukocyte activation. Nucleic acids encoding proteins and proteins so encoded which are capable of modulating leukocyte activation are provided. Compositions and methods for the treatment of disorders related to leukocyte dysfunction or dysregulation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating leukocyte activation.